We want to improve health and well-being for everyone, worldwide. We believe that our biosensor technology will become a significant global player in non-invasive testing and screening of diseases and wellbeing while also helping in the discovery of new disease biomarkers.

We want to work with inspiring people who share our goals and values. Let’s change the world for the better, together.

Aqsens Health’s E-TRF combined with the chemical- and biosensors delivers an exceptional amount of information of specific disease targets at a low cost. It helps in the discovery of new disease biomarkers and enables safer and more cost-efficient screening of different diseases from cancers to infectious diseases.

We’re well connected globally and have ongoing research and validation projects in Finland, China, Ghana and the US. Our business strategy aims to benefit both the developed world and low-and middle income countries.

The size of the in-vitro diagnostic market was over 80 billion dollars in 2022, and the market is expected to grow at a CAGR of 6.6%. Non-invasive diagnostics, such as urine and saliva based testing, are gaining in market share and becoming a high growth segment with clear competitive advantages over blood based testing. They offer new possibilities in finding new biomarkers and are also a more cost-efficient way to detect health disorders.

The in-vitro diagnostic market in the European Union is projected to reach 18 billion dollars by 2027. The largest segments within the IVD market are infectious disease and cancer diagnostics.

The in-vitro diagnostics market in China is rapidly growing and is expected to reach 17 billion dollars in 2023. The large aging population needs better and more cost-efficient diagnostics to manage the growing prevalence of chronic and infectious diseases.

Aqsens Health's E-TRF method and disease specific biosensors enable the systematic discovery process of new disease biomarkers from urine and saliva. We operate in a high growth area in which global diagnostic companies are gradually entering using traditional analytical measurement methods. The E-TRF and biosensor technology is well protected with a patent portfolio and it has the potential to revolutionize disease diagnostics in the coming years.

Aqsens' team consists of science-driven professionals in the field of biosensors and disease detection. We work closely together with dedicated clinical and scientific institutes and advisors, who are world-class medical professionals within their own fields.

As a company we are looking for 5 - 10 x ROI for the coming 3 to 5 years.